Health
Johnson & Johnson enrolls about 45000 participants for late-stage Covid-19 vaccine trial – The Straits Times
J&J said it plans to submit an emergency use authorisation application to the US FDA in February if the data from the study is safe and effective.. Read more at…
NEW JERSEY (REUTERS) – Johnson & Johnson said on Thursday (Dec 17) that it has enrolled about 45,000 participants for the first late-stage trial of its Covid-19 single-dose vaccine candidate and that it expects interim data by late-January.
The company, however, is lagging behind rivals Pfizer Inc and Moderna Inc in the race for a vaccine to combat the Covid-19 pandemic that has infected about 75 million people globally.
J&J’s study, named Ensemble, is being conducted by its unit Janssen, the drugmaker…
-
Business22 hours agoForget CBA and buy these high-yield ASX dividend shares
-
Noosa News23 hours ago“There’s No Going Back”: The Grid Meets the Real World in the Initial Trailer for Third ‘TRON’ Movie ‘Ares’
-
Business23 hours agoTop brokers name 3 ASX shares to buy next week 6 April 2025
-
Business23 hours agoHere’s a starter portfolio of ASX 200 shares to consider for growth, dividends, and value!